Literature DB >> 18434233

Impaired cognitive performance in Parkinson's disease is related to caudate dopaminergic hypofunction and hippocampal atrophy.

Pekka Jokinen1, Anna Brück, Sargo Aalto, Sarita Forsback, Riitta Parkkola, Juha O Rinne.   

Abstract

Frontal lobe dysfunction and other cognitive deficits have been described in Parkinson's disease (PD), which may lead to dementia. Both striatal dopaminergic deficiency and regional or global brain volume loss have been suggested to contribute to cognitive decline in PD. We therefore performed a neuropsychological evaluation, structural brain MRI and Fdopa PET in patients with PD and healthy elderly volunteers. PD patients had impaired cognitive performance in many neuropsychological tests compared to controls, not limited just to frontal lobe function tests. Caudate Fdopa correlated positively with performance in verbal (immediate and delayed) and visual memory. Patients with PD showed atrophy in the hippocampus and the prefrontal cortex and hippocampal atrophy was related to impaired memory. Our findings suggest that striatal dopaminergic depletion and global brain volume loss contribute to cognitive impairment in non-demented PD patients, but dysfunction of extra-striatal dopaminergic or non-dopaminergic systems probably plays a role especially in more generalized cognitive impairment.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18434233     DOI: 10.1016/j.parkreldis.2008.03.005

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  57 in total

1.  An update on brain imaging in parkinsonian dementia.

Authors:  Myria Petrou; Vikas Kotagal; Nicolaas I Bohnen
Journal:  Imaging Med       Date:  2012-04

Review 2.  Neuroimaging and cognition in Parkinson's disease dementia.

Authors:  Lisa C Silbert; Jeffrey Kaye
Journal:  Brain Pathol       Date:  2010-05       Impact factor: 6.508

Review 3.  Biomarkers for cognitive impairment in Parkinson disease.

Authors:  Min Shi; Bertrand R Huber; Jing Zhang
Journal:  Brain Pathol       Date:  2010-05       Impact factor: 6.508

4.  Neurocognitive and atrophic patterns in Parkinson's disease based on subjective memory complaints.

Authors:  Jin Yong Hong; Ji Eun Lee; Young H Sohn; Phil Hyu Lee
Journal:  J Neurol       Date:  2012-08       Impact factor: 4.849

5.  Brain Activity Associated With Attention Deficits Following Chemotherapy for Childhood Acute Lymphoblastic Leukemia.

Authors:  Slim Fellah; Yin T Cheung; Matthew A Scoggins; Ping Zou; Noah D Sabin; Ching-Hon Pui; Leslie L Robison; Melissa M Hudson; Robert J Ogg; Kevin R Krull
Journal:  J Natl Cancer Inst       Date:  2019-02-01       Impact factor: 13.506

6.  Multimodal dopaminergic and free-water imaging in Parkinson's disease.

Authors:  Jing Yang; Derek B Archer; Roxana G Burciu; Martijn L T M Müller; Arnab Roy; Edward Ofori; Nicolaas I Bohnen; Roger L Albin; David E Vaillancourt
Journal:  Parkinsonism Relat Disord       Date:  2019-01-06       Impact factor: 4.891

7.  Neuropsychologic assessment in collaborative Parkinson's disease research: a proposal from the National Institute of Neurological Disorders and Stroke Morris K. Udall Centers of Excellence for Parkinson's Disease Research at the University of Pennsylvania and the University of Washington.

Authors:  G Stennis Watson; Brenna A Cholerton; Rachel G Gross; Daniel Weintraub; Cyrus P Zabetian; John Q Trojanowski; Thomas J Montine; Andrew Siderowf; James B Leverenz
Journal:  Alzheimers Dement       Date:  2012-11-16       Impact factor: 21.566

8.  Verbal memory is associated with structural hippocampal changes in newly diagnosed Parkinson's disease.

Authors:  Mona K Beyer; Kolbjorn S Bronnick; Kristy S Hwang; Niels Bergsland; Ole Bjorn Tysnes; Jan Petter Larsen; Paul M Thompson; Johanne H Somme; Liana G Apostolova
Journal:  J Neurol Neurosurg Psychiatry       Date:  2012-11-15       Impact factor: 10.154

9.  Progression of brain atrophy in the early stages of Parkinson's disease: a longitudinal tensor-based morphometry study in de novo patients without cognitive impairment.

Authors:  Carlo Tessa; Claudio Lucetti; Marco Giannelli; Stefano Diciotti; Michele Poletti; Sabrina Danti; Filippo Baldacci; Claudio Vignali; Ubaldo Bonuccelli; Mario Mascalchi; Nicola Toschi
Journal:  Hum Brain Mapp       Date:  2014-01-22       Impact factor: 5.038

10.  Brain (18)F-DOPA PET and cognition in de novo Parkinson's disease.

Authors:  Agnese Picco; Silvia Morbelli; Arnoldo Piccardo; Dario Arnaldi; Nicola Girtler; Andrea Brugnolo; Irene Bossert; Lucio Marinelli; Antonio Castaldi; Fabrizio De Carli; Claudio Campus; Giovanni Abbruzzese; Flavio Nobili
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-03-28       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.